Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jun Nagamine"'
Autor:
Jun Nagamine
Publikováno v:
Folia Pharmacologica Japonica. 158:193-202
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ab3965ddd13a918f32dc774eee4cbfa
https://doi.org/10.1254/fpj.22095
https://doi.org/10.1254/fpj.22095
Autor:
T. Goto, M. Yamanaka, R. Nagata, Makoto Takata, R. Nakayama, T. Takazawa, A. Tsuchida, Katsunori Maruta, K. Watanabe, H. Kato, Jun Nagamine
Publikováno v:
Experimental and Clinical Endocrinology & Diabetes. 123:492-499
Aims/Introduction: Peroxisome proliferator-activated receptors (PPARs) play a key regulating role in homeostasis. In this study, we investigated the effects of DSP-8658, a novel selective PPARa/γ modulator, on adipogenesis and glucose metabolism in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfe1fa056c90168c004567e00a6c36e4
https://doi.org/10.1055/s-0035-1549965
https://doi.org/10.1055/s-0035-1549965
Autor:
Toshinori Kojima, Jun Nagamine
Publikováno v:
KAGAKU KOGAKU RONBUNSHU. 36:237-242
二酸化炭素問題の対策技術の一つとして，資源量が豊富である岩石の風化反応に注目した．しかしながら，岩石を利用する対策技術では，その風化反応速度は遅く，その反応速度がネッ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5627b00456a9c2a79a136f6413470abb
https://doi.org/10.1252/kakoronbunshu.36.237
https://doi.org/10.1252/kakoronbunshu.36.237
Autor:
Eiji Sugaru, Mutsuo Taiji, Teruhisa Tokunaga, Jun Nagamine, Makoto Kitoh, Michiko Ono-Kishino, Ryu Nagata, Tsutomu Nakagawa, Tsuyoshi Tsujimura
Publikováno v:
Biomedical Research. 30:177-182
Pulmonary fibrosis is a progressive and lethal lung disease characterized by accumulation of ECM and loss of pulmonary function. However, no cure exists for this disease, and current treatments often fail to slow its progression or relieve its sympto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82cf8a4ead6f3be3cc2108de5226fe4e
https://doi.org/10.2220/biomedres.30.177
https://doi.org/10.2220/biomedres.30.177
Autor:
Mutsuo Taiji, Makoto Kitoh, Tsutomu Nakagawa, Eiji Sugaru, Jun Nagamine, Tsuyoshi Tsujimura, Michiko Ono-Kishino, Ryu Nagata, Teruhisa Tokunaga
Publikováno v:
Biological and Pharmaceutical Bulletin. 32:1991-1996
The number of patients with chronic kidney disease (CKD) has continuously grown worldwide. Treatment with antihypertensive agents reduces the rate of progression of CKD, however, there is still a large unmet need to develop strategies for the treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcef10ef2d8f297b858a18927bc126a8
https://doi.org/10.1248/bpb.32.1991
https://doi.org/10.1248/bpb.32.1991
Autor:
Eiji Sugaru, Jun Nagamine, Tsuyoshi Tsujimura, Ryu Nagata, Michiko Ono-Kishino, Makoto Kitoh, Tsutomu Nakagawa, Teruhisa Tokunaga, Mutsuo Taiji
Publikováno v:
Nephron Experimental Nephrology. 110:I-VI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52723a0684c51a3d50d27ce0c239b776
https://doi.org/10.1159/000187123
https://doi.org/10.1159/000187123
Autor:
Jun Nagamine, Ryu Nagata, W. Ewan Hume, Mutsuo Taiji, Eiji Sugaru, Makoto Kitoh, Michiko Ono-Kishino, Tsutomu Nakagawa, Teruhisa Tokunaga
Publikováno v:
Nephron Experimental Nephrology. 105:e45-e52
Background/Aims: Diabetic nephropathy is the main cause of end-stage renal disease. Previously we have demonstrated that SMP-534 (an antifibrotic agent) prevents the development of diabetic nephropathy in db/db mouse and that combined treatment with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9467a4af139c1cbc5db0c4c50e1cea53
https://doi.org/10.1159/000097603
https://doi.org/10.1159/000097603
Autor:
Makoto Kitoh, Tsutomu Nakagawa, Mutsuo Taiji, Ryu Nagata, Jun Nagamine, Teruhisa Tokunaga, Eiji Sugaru, Michiko Ono-Kishino, W. Ewan Hume
Publikováno v:
American Journal of Physiology-Renal Physiology. 290:F813-F820
Diabetic nephropathy is currently the most common cause of end-stage renal disease. Diabetic nephropathy patients, whether insulin dependent or not, develop fibrotic changes in glomeruli that manifest as overt nephropathy. Previously, we demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b9c1239543da8640e2eeb57965635a8
https://doi.org/10.1152/ajprenal.00357.2005
https://doi.org/10.1152/ajprenal.00357.2005
Publikováno v:
Biomedical Research. 27:191-195
Growth hormone (GH) replacement therapy has been shown to have beneficial effects on linear growth enhancement in GH-deficient children over the past few decades. SMP-140 is a sterile liquid formation containing rhGH that is expected to improve patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5706edb7b5a6b8aaf0a74081feb7e9a3
https://doi.org/10.2220/biomedres.27.191
https://doi.org/10.2220/biomedres.27.191
Autor:
Makoto Kitoh, Ryu Nagata, W. Ewan Hume, Tsutomu Nakagawa, Mutsuo Taiji, Michiko Ono-Kishino, Jun Nagamine, Teruhisa Tokunaga, Eiji Sugaru
Publikováno v:
American Journal of Nephrology. 26:50-58
Background/Aims: Diabetic nephropathy is now the most common cause of end-stage renal disease. It is also clear that the current therapy, angiotensin II blockage, cannot prevent the progression of diabetic nephropathy. We had previously demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94d15edcf678c10c8a20a9cc07d5f519
https://doi.org/10.1159/000091786
https://doi.org/10.1159/000091786